Alvesco (ciclesonide) / Korea University Medical Center, Teijin, AstraZeneca, Covis Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
NCT02221375: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Completed
1
56
Europe
BHT low, BHT medium, BHT high, BI 54903 XX low, BI 54903 XX medium 1, BI 54903 XX medium 2, BI 54903 XX high, Ciclesonide
Boehringer Ingelheim
Healthy
09/08
 
NCT01371786: A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler

Completed
1
14
Europe
ciclesonide nasal aerosol, mometasone Aqueous (AQ) nasal spray
Sunovion
Allergic Rhinitis (AR)
08/11
08/11

Download Options